Wednesday 18 November 2026 Edition compiled at 07.45 NL EN FR
← Economy
EconomyUmicore

Insects in a process tank and hundreds of anomalous tests: US FDA rebukes Umicore over a plant in Argentina

The site near Buenos Aires makes ingredients for cancer drugs, and the US regulator calls its quality control inadequate.

· latest source update di · 3 sources · FDA, Urgente24, Radio Master Luján
Illustration for this article

The US medicines regulator FDA has sent a warning letter to Umicore Argentina, the Argentine subsidiary of the Belgian materials group. The letter is dated 6 November and was made public on Tuesday. According to Argentine news site Urgente24, it is addressed to Umicore chief executive Bart Sap. It concerns a plant in the industrial park of Pilar, near Buenos Aires, that makes active pharmaceutical ingredients based on platinum metals. According to Radio Master Luján, these go into cancer drugs used in hospitals; in 2018 the company listed cisplatin, carboplatin and oxaliplatin among them.

FDA inspectors visited the site from 4 to 9 June. According to the letter, the plant has had more than 300 test results outside specification since 2021, more than 200 of which were invalidated without thorough investigation. Human error was often named as the cause and retraining staff was considered sufficient. The inspectors also saw live insects in production areas, an insect at the bottom of a process tank, residues on equipment that should have been clean and standing water in a line.

The FDA therefore regards the ingredients as not complying with US law and considers the company's earlier responses insufficient. Umicore Argentina has fifteen working days to respond. Urgente24 notes that the FDA has no direct enforcement powers in Argentina but may inspect plants that supply the US market.

Argentine reports include no response from Umicore. Nothing is known yet about further steps such as an import ban or a recall.

Spotted a mistake in this article? Let us know.